Comparative Study of Efficacy between Pregabalin and Epalrestat in Diabetic Peripheral Neuropathic (Dpn) Pain

Diabetic neuropathies are a family of nerve disorders caused by diabetes. People with diabetes can, over time, develop nerve damage throughout the body. A total of fifty patients having diabetic neuropathic pain are recruited based on the inclusion and exclusion criteria. At first visit, patients are randomly assigned to one of the two treatment groups either Epalrestat or Pregabalin. Statistical analysis using student unpaired t-test. The scales used are Dallas pain questionnaire scale, Pain drawing scale, Lower extremity function scale; Biothesiometry score and plasma glucose post prandial. In the Dallas pain questionnaire scale, Pain drawing scale, Lower extremity function right and left toe scale in visit II and visit III are is P>0.05 significant value. In the Biothesiometry score right and left toe scale the ‘p’ value is  0.0445 and it is <0.05, it has found that the reduction of PGPP between two treatment groups during visit II and III is statistically differs. The study concludes that there was rapid reduction of pain scores in pain rating scale; biothesiometry scores and reduction of PGPP levels are more in Pregabalin therapy when compared to Epalrestat therapy. The above information indicates that the efficacy observed for diabetic peripheral neuropathic pain relief, was more with Pregaballin therapy at a dose of 150 mg daily.

Diabetic neuropathy has been defined as a demonstrable disorder, either clinically evident or subclinical, that occurs in the setting of diabetes without other causes for peripheral neuropathy. It includes manifestations in the somatic and/or autonomic parts of the peripheral nervous system.

In the biothesiometry scores analysis at 2nd and 3rd visit, the onset of pain relief was rapid, with significant efficacy was observed in the Pregabalin group at a dose of 150mg daily group than Epalrestat group at a dose of 150mg daily. The study shows that there was rapid reduction of pain scores in pain rating scale; biothesiometry scores and reduction of PGPP levels are more in Pregabalin therapy when compared to Epalrestat therapy. The above information indicates that the efficacy observed for diabetic peripheral neuropathic pain relief, was more with Pregaballin therapy at a dose of 150 mg daily. The study emphasizes the importance of early reduction of peripheral neuropathy among diabetic patients using simple affordable tools and methods to reduce mortality and diabetic peripheral neuropathy.

Asian Journal of Biomedical and Pharmaceutical Science accept Editorial, letter, case reports, short communications, original and review articles from leading scientists and scholars around the world in all areas of food, nutrition, biochemistry, physiology, pathology and medicine.

Authors can directly submit the article as an attachment to this online: https://www.scholarscentral.org/submissions/asian-biomedical-pharmaceutical-sciences.html

The articles once published can be accessed freely.

Media Contact:
Annie Grace Sarah
Journal Manager
Asian Journal of Biomedical and Pharmaceutical Sciences
Email: jbiopharm@epharmajournal.com